Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Photocure ASA: Results for the first quarter of 2017

Oslo, Norway, 23 May 2017: Photocure ASA (OSE: PHO) today reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the new growth strategy towards 2020. "Hexvix/Cysview delivered strong growth in major markets, outside the Nordic regions, during the first quarter. In particular, we saw good momentum in the US, driven by strong demand for Cysview. As

Summa Equity builds platform for big-data enabled businesses

23 May 2017 Summa Equity establishes Summa Digital – a platform for big data enabled businesses with ground breaking technologies within their respective field. The platform holds three businesses that Summa Equity has added to its portfolio.Summa Equity has invested in Swedish IVBAR Institute AB, Norwegian Documaster AS and UK-based Qlearsite Ltd. All three companies are early actors with leading solutions within different areas of big data solutions. Christian Melby, Partner at Summa Equity said: “The field of data analytics is growing exponentially. Niche markets are developing

Bydureon EXSCEL trial meets T2D safety objective

This announcement contains inside information 23 May 2017 07:00 BST BYDUREON EXSCEL TRIAL MEETS PRIMARY SAFETY OBJECTIVE IN TYPE-2 DIABETES PATIENTS AT WIDE RANGE OF CARDIOVASCULAR RISK Based on a composite measure of major adverse CV events (MACE), Bydureon did not increase cardiovascular (CV) risk and showed a consistent safety profile Fewer CV events were observed in the Bydureon arm, however, the efficacy objective of reduction in CV risk did not reach statistical significance AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of

Algol: Providing value since 1894

Algol sees their role in the internationalisation of Finland’s economy as more important than ever.To build high you need sturdy foundations, and few Finnish companies have stronger foundations than Algol. In 1894 they began life by importing industrial goods needed by Finnish businesses. They do the same thing today, and are even owned by the same family. Magnus and Alexander Bargum are father and son, representing the third and fourth generations of Algol owners. Magnus is on the board of directors while Alexander is Group CEO. Algol has operations in eleven countries and is a

Bactiguard wins tender for Stockholm

Bactiguard has won a tender for urinary catheters for the Stockholm county council, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters. The contract is valid for 2 years and can be extended for another 2 years."The Stockholm county council is Sweden’s largest region and this is the largest tender for urinary catheters in the country. Several other regions have already included our products in their tenders, and the fact that Stockholm now also has taken this decision is an important milestone and acknowledgement of

The winner of Clas Ohlson Product Innovation Challenge is appointed!

The Clas Ohlson Product Innovation Challenge is completed, and the winning contribution is “Altered:Nozzle”, the tap nozzle that reduces water consumption by up to 98%. This winning product will be launched by the end of June 2017, and be available in all of Clas Ohlson’s markets and sales channels.All too often, we leave the tap running while we perform our daily routines, say when brushing our teeth, doing dishes, washing our hands, cooking – as if water were an endless resource. The winners of Clas Ohlson Product Innovation Challenge have developed a new type of nozzle that easily fits

Strategic partnership between Elekta and BESA to improve clinical workflows

HELSINKI, May 23, 2017 – Elekta (EKTA-B.ST) announced today that Elekta Oy, a fully-owned subsidiary of Elekta AB and a global leading provider of magnetoencephalography (MEG) technology, has entered a long-term strategic partnership with BESA GmbH. The purpose of the partnership is to jointly develop and commercialize clinical software solutions for MEG, with the initial aim of providing a world-class workflow for the pre-surgical evaluation of epileptic patients. The collaboration will later expand to other clinical uses of the Elekta Neuromag® TRIUX™  MEG

Interim Report First Quarter 2017

First quarter · Net sales increased by 7% to SEK 115.0 (107.4) million. Adjusted to fixed exchange rates, net sales also increased by 7%. · Adjusted operating profit increased by 31% to SEK 44.4 (34.0) million. · Adjusted profit before tax increased by 43% to SEK 35.3 (24.6) million. · In February 2017, Diamorph AB (publ) acquired the final 10% of Diamorph Bearings AB and so today controls 100% of each of its subsidiaries. · In March 2017, Diamorph AB (publ) used part of the group’s surplus cash resources to make a voluntary partial repayment of SEK 50 million of its

Eltel’s Nomination Committee proposes Markku Moilanen as a new board member and revises its proposals for the AGM 2017 concerning the Board

Press release: 23.5.2017 at 8.00 CET The Nomination Committee of Eltel AB has unanimously resolved to propose Markku Moilanen as new member of Eltel’s Board of Directors. On 2 May 2017, the Nomination Committee announced its proposals for Eltel AB’s Annual General Meeting (AGM) to be held on 1 June 2017. The Nomination Committee hereby announces its revised proposal concerning the members of the Board of Directors to be presented at the AGM.Number of members of the Board of Directors Seven ordinary members of the Board of Directors with no deputy members. The remuneration for the

Ovako launches M-Steel Calculator – a digital service tool

Ovako has launched the M-Steel Calculator, a digital tool based on the company’s Steel Navigator platform, which guides customers in identifying the right machine settings based on steel properties and cutting tools. The M-Steel Calculator also allows customers to compare tool life and cutting speeds between M-Steel® from Ovako and conventional steel.“We are pleased to be able to offer our customers the M-Steel Calculator for comparison and verification of the correct machine settings. Similar digital tools on the market have until now been based only on the equipment and not the type of

Read original

Magnolia Bostad signs agreement to acquire two properties in Huddinge

Magnolia Bostad signs agreement to acquire Spendrup's old brewery, the properties Gambrinus 2 and Gambrinus 4, in Vårby. Magnolia Bostad will initiate work for a local plan for primarily residential purposes, comprising the development of approximately 1,500 residential unitsThe acquisition is covered by the framework agreement signed by Magnolia Bostad in November 2016 with Slättö. With the acquisition, Magnolia Bostad has signed agreements for all projects covered by the framework agreement. In total, the framework agreement comprises 13 residential projects, to be developed and sold to

Multiconsult ASA - Notice of extraordinary general meeting

An extraordinary general meeting of Multiconsult ASA will be held on 23 June 2017 at 12:00 CET at Felix Konferansesenter, Bryggetorget 3, Aker Brygge, Oslo.Notice of the extraordinary general meeting is attached hereto. All the documents to be processed at the extraordinary general meeting are available on the company's website www.multiconsult-ir.com. For more information, please contact:    Investor relations:           Mirza Koristovic, Head of Investor Relations           Phone: +47 93 87 05 25          E-mail: ir@multiconsult.no    Media:          Gaute Christensen,

Published preclinical results confirm IdeS potential in cancer immunotherapy

Hansa Medical AB (publ), a biopharmaceutical company developing novel immunomodulatory enzymes, announced today that preclinical data have been published in the peer-reviewed journal, Molecular Cancer Therapeutics (Järnum et al., Mol Cancer Ther May 22 2017 DOI: 10.1158/1535-7163.MCT-17-0108), confirming the potential of the company’s lead candidate IdeS in cancer immunotherapy.The published findings demonstrate how pre-treatment with IdeS in tumour animal models can increase the efficacy of currently available antibody based cancer therapies. Christian Kjellman, Senior Vice President R&

Multiconsult ASA - Proposal for new legal structure

The Board of Multiconsult ASA proposes to establish a new legal structure for the Multiconsult group. The company’s Norwegian operational activities will be demerged and then merged into a wholly-owned subsidiary. The purpose of the new legal structure is to establish a more efficient legal structure for the Multiconsult group.The Board of Multiconsult ASA has therefore decided to propose to its shareholders that the company’s business, as defined in a demerger plan dated 15 May 2017, is demerged to the newly established company MC Newco AS, followed by a merger of the business into

Appointment of new CEO of Hunter Group ASA, new chairman of Dwellop AS and a related party transaction

The board of directors of Hunter Group ASA ("Hunter Group" or the "Company") has appointed Mr. Vegard Urnes as new interim Chief Executive Officer ("CEO") of Hunter Group. To this effect, the Company has entered into a consultancy agreement with Middelborg AS, where Mr. Urnes is employed as Investment Manager. His employment as CEO in Hunter Group takes effect immediately. Mr. Urnes has over 15 years of experience from corporate finance, with main focus on the oil service sector. Mr. Urnes has previously worked with corporate finance at Goldman Sachs, ProCorp and NRP Securities, before

Director and Management share purchases and Orderly Market Agreements

The Marketing Group plc (“TMG” or the “Company” or the “Group”) is pleased to announce that it has been notified of the director and management share purchases detailed below.  Additionally, TMG is pleased to provide an update on the number of shareholders who have entered into the Orderly Market Agreement with the Company.Share Purchases Adam Graham, the Group’s CEO, has acquired 300,000 ordinary shares in the Company (“Shares”) at €0.75 per Share for a total value of €225,000 in an off market transaction with another shareholder.  Following this acquisition Adam Graham’s total

Kieku – the new personalised audio listening stream

Kieku  Labs, a Finnish independent media startup, today launched a new kind of audio listening service. Kieku’s key content aims to feed your mind with topics revolving around entrepreneurship and society, wellbeing and real-life stories. Based on machine learning, an algorithm generates a custom-made feed just for you, taking into account the types of content you listen to and the ones you skip. The beta service is available on kieku.com and initially as an iOS app in the Nordics and Estonia. “Imagine being stuck in traffic - radio plays content that is not

BrightCharger - charge in safety and protect your device battery life with a single touch

BrightCharger  aims to change the way people charge their devices. The innovative quality charger automatically stops devices from charging when their batteries are full, which protects battery lifespans, decreases hazards and eliminates energy wastage. The device also functions as a low energy consumption nightlight. With latest estimates currently placing the number of mobile devices at 12 billion, BrightCharger wants to help users make an impact on global consumption by giving them a simple way to responsibly charge various devices. “By using

Herantis Pharma granted a U.S. patent on therapeutic use of MANF

Herantis Pharma granted a U.S. patent on therapeutic use of MANF Herantis Pharma PlcCompany release 23 May 2017 at 9:00 am The United States Patent and Trademark Office ("USPTO") has issued to Herantis Pharma Plc ("Herantis") a patent titled "Neurotrophic factor MANF and uses thereof".  The patent number 9,592,270 is for the use of MANF, or mesencephalic astrocyte-derived neurotrophic factor, for the treatment of neurological diseases including Parkinson's disease, epilepsy, and ischemic brain injury. "MANF is the only known neurotrophic and neuroprotective factor similar to our

BerGenBio ASA: Results for the First Quarter 2017

Bergen, Norway, 23 May 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2017. A presentation of the results by the company’s senior management team will take place today at 10:00a.m. CET in Oslo - details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “During Q1 2017, BerGenBio has established a strong foundation from which to advance our development strategy for BGB324, a first-in-class, selective, oral Axl inhibitor,

EVRY intends to apply for a listing on Oslo Børs

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE LOCAL SECURITIES LAWS OR REGULATIONS OF SUCH JURISDICTION. EVRY AS (“EVRY” or the “Company”) today announces its intention to launch an initial public offering (the "IPO") of its ordinary shares and to apply for a listing on Oslo Børs.The IPO will support EVRY’s strategy and growth plans, through contributing to further enhancement of EVRY’s public profile, and

BAKKAFROST: Operational EBIT of DKK 335 million for the first quarter of 2017

The Bakkafrost Group delivered a total operating EBIT of DKK 335.5 mil­lion in Q1 2017. Harvested volumes were 13.2 thousand tonnes gutted weight. The combined farming and VAP segments made an operational EBIT of DKK 320.2 million. The farming segment made an operational EBIT of DKK 373.2 million. The salmon spot prices continued in Q1 2017 on a high level from 2016, which was positive for the farming segment. The VAP segment realized higher prices, but is not matched by the high spot prices, and therefore the VAP segment had negative margins in Q1 2017. The VAP segment made an operational

Storebrand Livsforsikring AS: Report on Solvency and financial condition 2016

Storebrand ASA makes public the electronic version of the Solvency and financial condition report 2016 at https://www.storebrand.no/en/investor-relations. Lysaker, 22 May 2017 Contact: Head of IR Kjetil Ramberg Krøkje: kjetil.r.krokje@storebrand.no or (+47) 934 12 155 Storebrand's ambition is to deliver better pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 1.9 million individual customers, and is

Storebrand ASA: Solvency and financial condition report 2016

Storebrand ASA makes public the electronic version of the Solvency and financial condition report 2016 at https://www.storebrand.no/en/investor-relations. Lysaker, 22 May 2017 Contact: Head of IR Kjetil Ramberg Krøkje: kjetil.r.krokje@storebrand.no or (+47) 934 12 155 Storebrand's ambition is to deliver better pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 1.9 million individual customers, and is

There are no items matching the current filter
There are no more items matching the current filter
Back to top